Skip to main content

Table 4 Multivariable-adjusted hazard ratios for the association between body fatness and ER/PR/HER2-defined subtypes of postmenopausal breast cancer

From: Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer

 

Luminal A-like (n = 3400)

Luminal B-like (n = 1324)

HER2-enriched (n = 235)

TNBC (n = 450)

phetb

Cases

MV-adjusted HR (95% CI)a

Cases

MV-adjusted HR (95% CI)a

Cases

MV-adjusted HR (95% CI)a

Cases

MV-adjusted HR (95% CI)a

BMI at wave 1c, d

Underweight

72

1.14 (0.90–1.44)

348

0.94 (0.63–1.40)

1

0.20 (0.03–1.40)

12

1.39 (0.78–2.48)

 

Normal weight

2038

Ref

852

Ref

154

Ref

271

Ref

 

Overweight

966

1.11 (1.02–1.20)

93

0.95 (0.84–1.08)

62

0.99 (0.73–1.33)

125

1.09 (0.88–1.35)

 

Obesity

303

1.13 (1.00–1.28)

6

0.81 (0.66–1.01)

18

0.91 (0.55–1.50)

41

1.14 (0.81–1.59)

 

ptrende

 

0.01

 

0.09

 

0.82

 

0.54

 0.06

Age at onset (yrs)f

BMI ≥ 25

 

Never OW

1780

Ref

736

Ref

136

Ref

247

Ref

 

< 40

609

1.10 (1.00–1.21)

212

0.90 (0.77–1.05)

39

0.90 (0.63–1.30)

83

1.03 (0.80–1.33)

 

40–49

698

1.27 (1.16–1.39)

230

1.00 (0.86–1.16)

46

1.11 (0.79–1.56)

74

0.95 (0.73–1.24)

 

≥ 50

313

1.04 (0.92–1.18)

146

1.18 (0.99–1.42)

14

0.68 (0.39–1.19)

46

1.12 (0.81–1.55)

 

ptrende

 

 < 0.01

 

0.14

 

0.41

 

0.66

 0.03

BMI ≥ 30

Never OB

3024

Ref

1199

Ref

216

Ref

403

Ref

 

< 40

63

0.90 (0.70–1.16)

18

0.63 (0.39–1.00)

5

0.96 (0.39–2.34)

7

0.70 (0.33–1.47)

 

40–49

145

1.10 (0.93–1.30)

51

0.95 (0.72–1.26)

11

1.11 (0.61–2.06)

22

1.20 (0.78–1.86)

 

≥ 50

168

1.23 (1.05–1.44)

56

1.03 (0.79–1.35)

3

0.34 (0.11–1.05)

18

0.98 (0.61–1.58)

 

ptrende

 

 < 0.01

 

0.87

 

0.12

 

0.87

0.29

Duration (per 10 yrs)f

BMI ≥ 25

1620

1.04 (1.00–1.07)

588

0.93 (0.88–0.99)

99

0.98 (0.86–1.12)

203

0.98 (0.89–1.08)

0.03

BMI ≥ 30

376

1.01 (0.93–1.10)

125

0.88 (0.76–1.03)

19

0.95 (0.67–1.34)

47

0.96 (0.76–1.22)

0.56

Intensity (per 100 units)f

OWY

1620

1.03 (0.96–1.11)

588

0.85 (0.74–0.97)

99

0.96 (0.70–1.30)

203

0.97 (0.78–1.20)

0.16

OBY

376

0.94 (0.75–1.18)

125

0.61 (0.38–0.99)

19

0.82 (0.31–2.15)

47

1.08 (0.63–1.86)

0.35

Trajectoriesg

Normal-stable

1413

Ref

601

Ref

107

Ref

205

Ref

 

Normal-overweight

1432

1.09 (1.01–1.18)

535

0.95 (0.84–1.06)

96

0.96 (0.73–1.27)

176

0.91 (0.74–1.11)

0.16

Normal-obesity

463

1.20 (1.08–1.33)

159

0.94 (0.78–1.12)

25

0.82 (0.53–1.28)

57

0.96 (0.72–1.30)

0.09

Overweight-obesity

77

1.05 (0.84–1.33)

21

0.64 (0.41–1.00)

6

1.00 (0.44–2.30)

9

0.78 (0.40–1.53)

0.3

Obesity-decrease

15

0.54 (0.33–0.90)

8

0.67 (0.33–1.35)

1

0.54 (0.08–3.88)

3

0.76 (0.24–2.37)

0.94

ptrende

 

0.07

 

0.05

 

0.42

 

0.37

 
  1. BMI body mass index, CI confidence interval, HR hazard ratio, HER2 human epidermal growth factor receptor 2, MV multivariable, OBY weighted cumulative obesity years, OWY weighted cumulative overweight years, p p-value, TNBC triple-negative breast cancer
  2. aAdjusted for age, age at menarche, parity, age at first birth, breast cancer in mother, smoking, MHT use
  3. bp heterogeneity between ER/PR/HER2-defined subtypes; likelihood ratio test by competing risks analysis
  4. cNumber of missing values: 21 luminal A-like (0.6%); 6 luminal B-like (0.5%); 0 HER2-enriched; 1 TNBC (0.2%)
  5. dUnderweight: < 18.5 kg/m2; normal weight: 18.5–24.9 kg/m2; overweight: 25–29.9 kg/m2; obesity: ≥ 30 kg/m2
  6. ep trend, continuous variable
  7. fBased on linear mixed effects models. Never overweight/obesity as reference group
  8. gBased on group-based trajectory modeling
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us